Veradermics (MANE) Accumulated Expenses (2024 - 2026)

Veradermics has reported Accumulated Expenses for 3 years, with the latest figure at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses changed N/A year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.6 million (changed N/A YoY), and the FY2025 full-year result was $7.0 million, up 182.55% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $7.0 million in Q4 2025, with the low at $2.5 million in Q4 2024.
• Historically, Accumulated Expenses has averaged $5.0 million across 3 years, with a median of $5.6 million in 2026.
• The largest YoY upside for Accumulated Expenses was 182.55% in 2025 against a maximum downside of 182.55% in 2025.
• Veradermics' Accumulated Expenses stood at $2.5 million in 2024, then surged by 182.55% to $7.0 million in 2025, then fell by 19.67% to $5.6 million in 2026.
• The last three Accumulated Expenses figures came in at $5.6 million (Q1 2026), $7.0 million (Q4 2025), and $2.5 million (Q4 2024), per Business Quant data.